Early ADHD Medication May Reduce Risk of Psychotic Disorders Later in Life

A new study has found that treating ADHD with stimulant medications during childhood may cut the risk of severe psychotic disorders in later life. Published in JAMA Psychiatry, the research suggests early intervention could offer long-term mental health benefits. Experts say the findings may ease concerns about the safety of these widely used drugs. The study focused on methylphenidate, a common ADHD medication, and tracked its effects over time. Researchers discovered that starting treatment before age 13 provided the strongest protective effect against conditions like schizophrenia. They used advanced statistical methods to adjust for differences in prescribing habits across regions.

Dr. Colm Healy, the lead author, highlighted the need for more age-specific research as ADHD diagnoses in adults rise. The team also found no evidence that methylphenidate increased the risk of psychosis later in life. Instead, the data suggested the opposite—a potential reduction in severe mental illness when treatment began early. Professor Ian Kelleher, who co-led the study, noted that the results could reassure families and clinicians worried about long-term medication risks. The researchers stressed the importance of early diagnosis, careful assessment, and evidence-based treatment for ADHD.

The findings challenge the belief that ADHD stimulants might trigger psychosis. Instead, they suggest early treatment could lower the risk of serious mental health problems in adulthood. Clinicians may now have stronger evidence to support the use of methylphenidate in younger children.